1 |
Factors Influencing Bariatric Patients’ Level of Compliance with Supplement Recommendations and Bioavailability of Iron Supplement Formulations in Roux-en-Y Gastric Bypass PatientsHaley R Snell-Sparapany (8083127) 06 December 2019 (has links)
<p>In our first study, we explored the barriers to complying
with iron supplement recommendations using focus groups. We recruited adults,
ages 18-75 years, who have had bariatric surgery at least two months previously
to participate in one of four 90-minute focus groups. Participants filled out a
survey asking for information on demographics and supplement use, and a
facilitator asked a set of pre-determined questions to each group. Responses were written, recorded, transcribed
using TranscribeMe (San Francisco CA), and analyzed using NVivo (QSR
International Pty Ltd, Doncaster, Victoria). The focus groups contained nineteen participants, five of which had
sleeve gastrectomy (SG) and fourteen had Roux-en-Y gastric bypass (RYGB). The
average age of the participants was 49.3 ± 9.4 years, and they had undergone surgery 3.9 ± 3.6 years previously. The key factors that
influenced participants’ adherence to supplement guidelines were cost,
tolerability, and palatability of the supplement, level of knowledge and
support from healthcare providers, and convenience of the supplementation
regime.</p>
<p>The
second study was a prospective observational study to determine the
bioavailability of ASP compared to FS. Iron deficient RYGB patients ages
18-65 years, who had surgery at least 6 months previously, participated in
8-hour iron absorption tests. Participants received a low-iron breakfast with
65 mg ASP (N=7) or FS (N=3). We assessed serum iron every 30 minutes for 8
hours following the supplementation using a colorimetric assay (South Bend
Medical Foundation, South Bend, IN). In
participants administered FS, serum iron increased 96.0 ± 27.2 µg/dL compared
to baseline, whereas with ASP, serum iron increased 5.8 ± 4.7
µg/dL compared to baseline (<i>P</i> = 0.02). These data indicate that ASP
is not as bioavailable as FS in RYGB patients.</p>
|
Page generated in 0.124 seconds